In this guest blog, Dale Greenwood, mental health lead for East London NHS Foundation Trust, shares how his trust implemented ...

The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs ...

Guidance programme Guidance programme Antimicrobial prescribing guidelines (20) Cancer service guidelines (8) Clinical guidelines (226) COVID-19 rapid guidelines (3) Diagnostics guidance (50) Health ...

More than 30,000 children and young people are living with type 1 diabetes in England. Usual management involves finger prick testing and injecting insulin multiple times a day. HCL systems remove the ...

The draft guideline recommends medicines be given up to a year earlier - helping people live well for longer. We’re updating the recommendations for drug treatments in our clinical guideline on the ...

NICE Guidance; Conditions and diseases; Blood and immune system conditions; Blood and bone marrow cancers; Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory ...

NICE leads the way in approving breakthrough treatment for multiple myeloma . People in England will become the first in the world to receive belantamab mafodotin for this indication following our ...

Evidence-based recommendation on linzagolix (Yselty) for treating symptoms of endometriosis in adults of reproductive age.. Last reviewed: 04 June 2025 Next review: This guidance will be reviewed if ...

Programme director for Healthtech strategy and development. Imagine a future where groundbreaking health technologies reach NHS patients in a matter of months rather than years. Where innovative ...

Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212] ...

Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.. Last reviewed: 04 June 2025 Next review: This guidance will be ...

Suggested remit: To appraise the clinical and cost effectiveness of encorafenib with binimetinib within its marketing authorisation for treating BRAF V600E mutation-positive advanced non-small-cell ...